Studieoverzicht
Study name: TAIHO
Histology | NSCLC | ||
---|---|---|---|
Tumor stage | Stage III - IV | ||
Host / recruiting site 1 | LUMC | Enrollment | Closed |
Therapy line | Later line (≥2L) | ||
Design |
Fase 1/2 studie naar veiligheid en effectiviteit van TAS3351 |
||
Intervention | TAS3351 is een orale 4e generatie EGFR TKI. |
||
Key outcome parameters |
|
||
Key inclusion criteria |
|
||
Key exclusion criteria |
|
||
Contact information | Log in voor de contactinformatie |